Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026

Pyxis Oncology, Inc.

Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.
Net loss of $21.2M ($0.35/share) vs $23.0M ($0.56/share) in Q3 2023.
R&D expenses rose to $17.7M from $14.7M due to increased clinical trial costs for PYX-201 and PYX-106.
Preliminary Phase 1 data for lead ADC PYX-201 to be presented at investor event on Nov 20, 2024; 80 patients dosed.
Phase 1 data for PYX-106 (Siglec-15 antibody) expected by year-end 2024; 45 patients dosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.